Skip to main content
SNYR
NASDAQ Life Sciences

Synergy CHC Faces Nasdaq Delisting Notice Over Late Q2 10-Q

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.108
Mkt Cap
$1.733M
52W Low
$0.087
52W High
$3.215
52W Position info
24% above low
Off High info
97% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SNYR sits 24% above its 52-week low of $0.087.

Summary

Synergy CHC Corp. received a Nasdaq delisting notice for failing to file its Q2 2026 Form 10-Q, adding to a series of recent distress signals including a loan default and loss of a major customer.


Key Events · Legal and Risk Events · SNYR

  • Nasdaq Delisting Notice Received

    On August 20, 2026, Synergy CHC Corp. received a notice from Nasdaq stating it is not in compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Q2 2026 Form 10-Q.

  • Compliance Deadlines Set

    The company has 60 days (until October 19, 2026) to submit a compliance plan, and Nasdaq may grant up to 180 days (until February 10, 2027) to regain compliance.

  • Uncertainty Over Filing

    The company cannot predict when or whether the Q2 Form 10-Q will be filed, and there is no assurance it will regain compliance.

  • Escalating Distress Signals

    This notice follows a default notice on the company's $17.6 million term loan on August 11, 2026, and the loss of Costco as a customer in July 2026.


Analysis · SNYR · Life Sciences

A Nasdaq notice on August 20, 2026, put Synergy CHC Corp. on notice for failing to file its Q2 2026 Form 10-Q on time. The company has 60 days to submit a compliance plan and could receive up to 180 days to regain compliance, but it cannot predict when or whether the filing will be completed. This adds to a cascade of distress: a default notice on its $17.6 million term loan on August 11, the loss of Costco as a customer in July, and a highly dilutive equity plan approved in June. The delisting notice is a critical governance and liquidity red flag that could lead to removal from Nasdaq, further impairing the company's ability to raise capital.

At the time of this filing, SNYR was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.09 to $3.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNYR - Latest Insights

SNYR
Aug 11, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.165
Real-time Price: $0.1098 info
Change: -$0.0552 (-33%) info
Market Cap: $1.733M info
SNYR
Jul 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.1597
Real-time Price: $0.1098 info
Change: -$0.0499 (-31%) info
Market Cap: $1.733M info
SNYR
Jun 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2073
Real-time Price: $0.1098 info
Change: -$0.0975 (-47%) info
Market Cap: $1.733M info
SNYR
May 18, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2861
Real-time Price: $0.1098 info
Change: -$0.1763 (-62%) info
Market Cap: $1.733M info
SNYR
May 15, 2026, 5:07 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.2821
Real-time Price: $0.1098 info
Change: -$0.1723 (-61%) info
Market Cap: $1.733M info